TOZASERTIB
Tozasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against aurora kinase C, aurora kinase A, and aurora kinase B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | — | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TOZASERTIB |
| INN | tozasertib |
| Description | N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide is a N-arylpiperazine. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 639089-54-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL572878 |
| ChEBI ID | — |
| PubChem CID | 5494449 |
| DrugBank | — |
| UNII ID | 234335M86K (ChemIDplus, GSRS) |
Target
Agency Approved
AURKB
AURKB
Organism
Homo sapiens
Gene name
AURKB
Gene synonyms
AIK2, AIM1, AIRK2, ARK2, STK1, STK12, STK5
NCBI Gene ID
Protein name
aurora kinase B
Protein synonyms
AIM-1, ARK-2, Aurora 1, aurora kinase B-Sv1, aurora kinase B-Sv2, Aurora- and IPL1-like midbody-associated protein 1, aurora- and Ipl1-like midbody-associated protein 1 homolog, aurora-1, aurora-B, Aurora-related kinase 2, Aurora/IPL1-related kinase 2, protein phosphatase 1, regulatory subunit 48, serine/threonine kinase 12, Serine/threonine-protein kinase 12, Serine/threonine-protein kinase 5, Serine/threonine-protein kinase aurora-B, STK-1
Uniprot ID
Mouse ortholog
Aurkb (20877)
aurora kinase B (Q8C6C1)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 405 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use